GlobalData on MSN1mon
Genentech wins FDA approval for second stroke treatment
whereas Activase is administered as an IV bolus followed by a one-hour infusion. The differences in administration come down ...
Renal & Urology News28d
FDA Approves TNKase for Acute Ischemic Stroke
The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...
PMLiVE1mon
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
TNKase, delivered as a single five-second IV bolus, offers a faster and simpler administration compared to Activase. The drug is also already approved in the US to treat acute ST-elevation myocardial ...
Pharmaceutical Technology1mon
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.